vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Ribbon Communications Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.1倍（$162.6M vs $152.6M），Ribbon Communications Inc.净利率更高（54.8% vs 34.5%，领先20.2%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -10.3%），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -8.1%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
CPRX vs RBBN — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $162.6M |
| 净利润 | $52.7M | $89.1M |
| 毛利率 | 82.9% | 42.9% |
| 营业利润率 | 40.5% | 37.6% |
| 净利率 | 34.5% | 54.8% |
| 营收同比 | 7.6% | -10.3% |
| 净利润同比 | -5.8% | — |
| 每股收益（稀释后） | $0.40 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $162.6M | ||
| Q4 25 | $152.6M | $227.3M | ||
| Q3 25 | $148.4M | $215.4M | ||
| Q2 25 | $146.6M | $220.6M | ||
| Q1 25 | $141.4M | $181.3M | ||
| Q4 24 | $141.8M | $251.4M | ||
| Q3 24 | $128.7M | $210.2M | ||
| Q2 24 | $122.7M | $192.6M |
| Q1 26 | — | $89.1M | ||
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $-12.1M | ||
| Q2 25 | $52.1M | $-11.1M | ||
| Q1 25 | $56.7M | $-26.2M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | $-13.4M | ||
| Q2 24 | $40.8M | $-16.8M |
| Q1 26 | — | 42.9% | ||
| Q4 25 | 82.9% | 53.3% | ||
| Q3 25 | 84.7% | 50.1% | ||
| Q2 25 | 85.9% | 49.6% | ||
| Q1 25 | 87.3% | 45.4% | ||
| Q4 24 | 84.7% | 55.7% | ||
| Q3 24 | 85.0% | 52.1% | ||
| Q2 24 | 87.4% | 50.8% |
| Q1 26 | — | 37.6% | ||
| Q4 25 | 40.5% | 4.1% | ||
| Q3 25 | 44.7% | 1.3% | ||
| Q2 25 | 45.2% | 1.9% | ||
| Q1 25 | 44.8% | -10.8% | ||
| Q4 24 | 44.3% | 13.2% | ||
| Q3 24 | 39.6% | -0.4% | ||
| Q2 24 | 44.2% | -1.0% |
| Q1 26 | — | 54.8% | ||
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | -5.6% | ||
| Q2 25 | 35.6% | -5.0% | ||
| Q1 25 | 40.1% | -14.5% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | -6.4% | ||
| Q2 24 | 33.2% | -8.7% |
| Q1 26 | — | $0.50 | ||
| Q4 25 | $0.40 | $0.50 | ||
| Q3 25 | $0.42 | $-0.07 | ||
| Q2 25 | $0.41 | $-0.06 | ||
| Q1 25 | $0.45 | $-0.15 | ||
| Q4 24 | $0.44 | $0.05 | ||
| Q3 24 | $0.35 | $-0.08 | ||
| Q2 24 | $0.33 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $67.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $419.1M |
| 总资产 | $1.1B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $67.6M | ||
| Q4 25 | $709.2M | $96.4M | ||
| Q3 25 | $689.9M | $74.8M | ||
| Q2 25 | $652.8M | $60.5M | ||
| Q1 25 | $580.7M | $71.2M | ||
| Q4 24 | $517.6M | $87.8M | ||
| Q3 24 | $442.3M | $37.2M | ||
| Q2 24 | $375.7M | $64.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $342.1M | ||
| Q3 25 | — | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
| Q1 26 | — | $419.1M | ||
| Q4 25 | $954.3M | $449.0M | ||
| Q3 25 | $920.2M | $360.1M | ||
| Q2 25 | $856.0M | $370.4M | ||
| Q1 25 | $794.3M | $381.8M | ||
| Q4 24 | $727.6M | $404.6M | ||
| Q3 24 | $660.9M | $395.5M | ||
| Q2 24 | $608.7M | $405.0M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $971.9M | $1.1B | ||
| Q1 25 | $908.9M | $1.1B | ||
| Q4 24 | $851.4M | $1.2B | ||
| Q3 24 | $772.0M | $1.1B | ||
| Q2 24 | $706.4M | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | — |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $29.2M | ||
| Q3 25 | $32.4M | $26.5M | ||
| Q2 25 | $71.3M | $-795.0K | ||
| Q1 25 | $60.0M | $-3.5M | ||
| Q4 24 | $70.9M | $61.8M | ||
| Q3 24 | $72.9M | $-14.8M | ||
| Q2 24 | $64.1M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $27.3M | ||
| Q3 25 | — | $21.0M | ||
| Q2 25 | $71.3M | $-6.5M | ||
| Q1 25 | — | $-15.7M | ||
| Q4 24 | $70.8M | $53.8M | ||
| Q3 24 | $72.6M | $-23.7M | ||
| Q2 24 | $64.1M | $-12.9M |
| Q1 26 | — | — | ||
| Q4 25 | 29.4% | 12.0% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | 48.6% | -2.9% | ||
| Q1 25 | — | -8.7% | ||
| Q4 24 | 49.9% | 21.4% | ||
| Q3 24 | 56.4% | -11.3% | ||
| Q2 24 | 52.3% | -6.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 6.7% | ||
| Q4 24 | 0.1% | 3.2% | ||
| Q3 24 | 0.2% | 4.2% | ||
| Q2 24 | 0.0% | 1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
